Join Growin Stock Community!
Beta
Back to NVO.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
cash-and-debt-chart

NVO Cash & Debt

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

As of Q1'26, Novo Nordisk's cash and short-term investments stood at $21.6B USD, reflecting a decline from the previous quarter's $27.0B USD, while total debt reached a record high of $146.4B USD, up from $131.0B USD in Q4'25. This positions the company's net cash position at a significant deficit of approximately -$124.8B USD, highlighting increased financial leverage amid ongoing operations. Over the period from Q2'23 to Q1'26, cash and short-term investments exhibited high volatility, fluctuating between a low of $9.3B USD in Q1'24 and a peak of $74.9B USD in Q3'24, with an overall downward trend averaging around $32.8B USD annually but showing no sustained growth pattern. In contrast, debt displayed a clear upward trajectory, rising steadily from $25.7B USD in Q2'23 to $146.4B USD in Q1'26, with notable accelerations post-Q1'24—including a sharp jump to $102.8B USD by Q4'24—driven by apparent expansions in borrowing, resulting in a deteriorating net debt position that could signal heightened risk for financial analysts monitoring liquidity ratios.